0000000000511064

AUTHOR

Jc Chen

showing 3 related works from this author

Rates, polarizations, and asymmetries in charmless vector-vector B meson decays

2003

With a sample of approximately 89 million BBbar pairs collected with the BABAR detector, we perform a search for B meson decays into pairs of charmless vector mesons (phi, rho, and K*). We measure the branching fractions, determine the degree of longitudinal polarization, and search for CP violation asymmetries in the processes B->phiK*+, B->phiK*0, B->rho0K*+, and B->rho0rho+. We also set an upper limit on the branching fraction for the decay B->rho0rho0.

Particle physicsMesonBABARElectron–positron annihilationHadronFOS: Physical sciencesGeneral Physics and AstronomyElementary particleResonancePARTICLE PHYSICS; PEP2; BABAR01 natural sciencesNOHigh Energy Physics - ExperimentHigh energy physicHigh Energy Physics - Experiment (hep-ex)Particle decayElectromagnetic calorimeterPolarizationProbability density function0103 physical sciences[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]PEP2B mesonDecay dynamic010306 general physicsPhysicsCalorimeter010308 nuclear & particles physicsBranching fractionCP-ASYMMETRIES VIOLATION SEARCH B->VVColliding beam acceleratorComputer simulationDecay rateMonte Carlo methodCrystallographyPARTICLE PHYSICSCP violationHigh Energy Physics::ExperimentParticle detectorProton
researchProduct

Searches for B0 decays to combinations of charmless isoscalar mesons

2004

We search for B meson decays into two-body combinations of eta, eta', omega, and phi mesons from 89 million B B-bar pairs collected with the BaBar detector at the PEP-II asymmetric-energy e+e- collider at SLAC. We find the branching fraction BF(B0 -> eta omega) = (4.0^{+1.3}_{-1.2} +- 0.4) x 10^-6 with a significance of 4.3 sigma. For all the other decay modes we set the following 90% confidence level upper limits on the branching fractions, in units of 10^-6 : BF(B0 -> eta eta)<2.8, BF(B0 -> eta eta')<4.6, BF(B0 -> eta' eta')<10, BF(B0 -> eta'omega)<2.8, BF(B0 -> eta phi)<1.0, BF(B0 -> eta' phi)<4.5, BF(B0 -> phi phi)<1.5.

IsoscalarElectron–positron annihilationBABARGeneral Physics and AstronomyQCD FACTORIZATION01 natural sciencesOmega13.25.Hw 11.30.Er 12.15.HhHigh Energy Physics - ExperimentHigh Energy Physics - Experiment (hep-ex)Mathematical modelProbability density function[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]PEP2B mesonNuclear ExperimentQCD FACTORIZATION; STANDARD MODEL; BABAR; SLACPhysicsQuantum chromodynamicsSigmaHamiltonianMonte Carlo methodSensitivity analysiPARTICLE PHYSICSBranching fractionSLACParticle physicsMesonSTANDARD MODELQCD FACTORIZATION STANDARD MODELFOS: Physical sciencesLikelihood distributionPARTICLE PHYSICS; PEP2; BABARSolenoidHigh energy physicNuclear physicsPhysics and Astronomy (all)ElectromagnetismElectromagnetic calorimeterPseudoscalar meson0103 physical sciencesPerturbation technique010306 general physicsCalorimeterError analysi010308 nuclear & particles physicsBranching fractionHEPMagnetic fieldHigh Energy Physics::Experiment
researchProduct

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

2017

Item does not contain fulltext BACKGROUND: Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. METHODS: In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent re…

MaleSTATIN THERAPYAnticholesteremic Agents/adverse effectsAntibodieVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Injections Subcutaneous/adverse effects030204 cardiovascular system & hematologyBococizumablaw.inventionPCSK90302 clinical medicineRandomized controlled triallawRisk FactorsGENETIC-VARIANTSCardiovascular DiseaseMonoclonalAnticholesteremic Agent030212 general & internal medicineMyocardial infarctionTreatment FailureHumanizedProprotein Convertase 9/antagonists & inhibitorsMedicine(all)Antibodies; Antibodies Monoclonal Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol LDL; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Injections Subcutaneous; Lipids; Male; Middle Aged; Proprotein Convertase 9; Risk Factors; Treatment Failure; Medicine (all)Anticholesteremic AgentsMedicine (all)PCSK9 InhibitorsAntibodies; antibodies monoclonal humanized; anticholesteremic agents; cardiovascular diseases; cholesterol LDL; double-blind method; female; follow-up studies; humans; hypercholesterolemia; injections subcutaneous; lipids; male; middle aged; proprotein convertase 9; risk factors; treatment failure; medicine (all)Vascular damage Radboud Institute for Molecular Life Sciences [Radboudumc 16]General MedicineLipidMiddle AgedLipids3. Good healthLDL/bloodMulticenter StudyCholesterolTRIALSCholesterol LDL/bloodCardiovascular DiseasesAntibodies Monoclonal Humanized/adverse effectsanticholesteremic agentsRandomized Controlled Trialsubcutaneouslipids (amino acids peptides and proteins)FemaleProprotein Convertase 9Cardiovascular Diseases/prevention & controlREDUCING LIPIDSHumanmedicine.medical_specialtyanimal structuresInjections SubcutaneousHypercholesterolemiaHypercholesterolemia/drug therapyPlaceboAntibodies Monoclonal HumanizedInjections SubcutaneouAntibodiesLDLInjectionsFollow-Up StudielipidsEVENTS03 medical and health sciencesantibodies monoclonal humanizedDouble-Blind MethodInternal medicinemedicineJournal ArticleHumansComparative StudyMETAANALYSISAlirocumabbusiness.industryUnstable anginaLipids/bloodPCSK9Risk FactorfungiAntibodies/bloodCholesterol LDLta3121medicine.diseaseSurgerycardiovascular diseasesEvolocumabREDUCTIONHumanized/adverse effectsSubcutaneous/adverse effectsbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies
researchProduct